Genetic polymorphisms and gene-dosage effect in ovarian cancer risk and response to paclitaxel/cisplatin chemotherapy
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1756-9966
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Genetic polymorphisms and gene-dosage effect in ovarian cancer risk and response to paclitaxel/cisplatin chemotherapy ; volume:34 ; number:1 ; day:16 ; month:1 ; year:2015 ; pages:1-11 ; date:12.2015
Journal of experimental & clinical cancer research ; 34, Heft 1 (16.1.2015), 1-11, 12.2015
- Creator
-
Tecza, Karolina
Pamula-Pilat, Jolanta
Kolosza, Zofia
Radlak, Natalia
Grzybowska, Ewa
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s13046-015-0124-y
- URN
-
urn:nbn:de:101:1-2021081410365461232259
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 3:59 PM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Tecza, Karolina
- Pamula-Pilat, Jolanta
- Kolosza, Zofia
- Radlak, Natalia
- Grzybowska, Ewa
- SpringerLink (Online service)
Other Objects (12)
Systemic exposure to cisplatin and paclitaxel after intraperitoneal chemotherapy in ovarian cancer
Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer
Neoadjuvant chemotherapy with weekly cisplatin and paclitaxel followed by chemoradiation for locally advanced cervical cancer
Interleukin 12 shows a better curative effect on lung cancer than paclitaxel and cisplatin doublet chemotherapy
Liposomal paclitaxel versus docetaxel in induction chemotherapy using Taxanes, cisplatin and 5-fluorouracil for locally advanced nasopharyngeal carcinoma
Cisplatin-functionalized silica nanoparticles for cancer chemotherapy
Cisplatin plus paclitaxel chemotherapy with or without bevacizumab in postmenopausal women with previously untreated advanced cervical cancer: a retrospective study
Mifepristone prevents repopulation of ovarian cancer cells escaping cisplatin-paclitaxel therapy
Combination therapy involving radiofrequency ablation and targeted chemotherapy with bevacizumab plus paclitaxel and cisplatin in a rabbit VX2 lung tumor model
Secondary sclerosing cholangitis after chemotherapy with bevacizumab and paclitaxel
Vergleich zweier neoadjuvanter Radiochemotherapien bei fortgeschrittenen Mundhöhlenkarzinomen : (Cis-Platin cersus Paclitaxel, Carboplatin)
Paclitaxel and cisplatin combined with intensity-modulated radiotherapy for upper esophageal carcinoma
Systemic exposure to cisplatin and paclitaxel after intraperitoneal chemotherapy in ovarian cancer
Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer
Neoadjuvant chemotherapy with weekly cisplatin and paclitaxel followed by chemoradiation for locally advanced cervical cancer
Interleukin 12 shows a better curative effect on lung cancer than paclitaxel and cisplatin doublet chemotherapy
Liposomal paclitaxel versus docetaxel in induction chemotherapy using Taxanes, cisplatin and 5-fluorouracil for locally advanced nasopharyngeal carcinoma
Cisplatin-functionalized silica nanoparticles for cancer chemotherapy
Cisplatin plus paclitaxel chemotherapy with or without bevacizumab in postmenopausal women with previously untreated advanced cervical cancer: a retrospective study
Mifepristone prevents repopulation of ovarian cancer cells escaping cisplatin-paclitaxel therapy
Combination therapy involving radiofrequency ablation and targeted chemotherapy with bevacizumab plus paclitaxel and cisplatin in a rabbit VX2 lung tumor model
Secondary sclerosing cholangitis after chemotherapy with bevacizumab and paclitaxel
Vergleich zweier neoadjuvanter Radiochemotherapien bei fortgeschrittenen Mundhöhlenkarzinomen : (Cis-Platin cersus Paclitaxel, Carboplatin)
Paclitaxel and cisplatin combined with intensity-modulated radiotherapy for upper esophageal carcinoma
Systemic exposure to cisplatin and paclitaxel after intraperitoneal chemotherapy in ovarian cancer
Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer
Neoadjuvant chemotherapy with weekly cisplatin and paclitaxel followed by chemoradiation for locally advanced cervical cancer
Interleukin 12 shows a better curative effect on lung cancer than paclitaxel and cisplatin doublet chemotherapy
Liposomal paclitaxel versus docetaxel in induction chemotherapy using Taxanes, cisplatin and 5-fluorouracil for locally advanced nasopharyngeal carcinoma
Cisplatin-functionalized silica nanoparticles for cancer chemotherapy
Cisplatin plus paclitaxel chemotherapy with or without bevacizumab in postmenopausal women with previously untreated advanced cervical cancer: a retrospective study
Mifepristone prevents repopulation of ovarian cancer cells escaping cisplatin-paclitaxel therapy
Combination therapy involving radiofrequency ablation and targeted chemotherapy with bevacizumab plus paclitaxel and cisplatin in a rabbit VX2 lung tumor model
Secondary sclerosing cholangitis after chemotherapy with bevacizumab and paclitaxel
Vergleich zweier neoadjuvanter Radiochemotherapien bei fortgeschrittenen Mundhöhlenkarzinomen : (Cis-Platin cersus Paclitaxel, Carboplatin)